Compare Stocks: SIGA, ANRO, TBPH, and COLL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.72 +2.4%	$27.77	$10.20 ▼ $37.48	$870.78M	1.42	613,380 shs	505,159 shs
COLL Collegium Pharmaceutical	$23.73 +0.2%	$23.16	$21.43 ▼ $50.79	$770.92M	0.75	622,329 shs	524,867 shs
SIGA Siga Technologies	$3.11 +5.4%	$3.19	$2.83 ▼ $8.46	$211.96M	1.1	492,298 shs	720,715 shs
TBPH Theravance Biopharma	$17.03	$17.04	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+2.75%	-2.05%	-8.27%	-19.19%	+86.72%
COLL Collegium Pharmaceutical	+0.21%	+3.17%	+7.77%	-33.59%	-34.27%
SIGA Siga Technologies	+5.42%	-2.81%	-7.99%	-1.27%	-62.07%
TBPH Theravance Biopharma	0.00%	0.00%	0.00%	+0.77%	+11.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.72 +2.4%	$27.77	$10.20 ▼ $37.48	$870.78M	1.42	613,380 shs	505,159 shs
COLL Collegium Pharmaceutical	$23.73 +0.2%	$23.16	$21.43 ▼ $50.79	$770.92M	0.75	622,329 shs	524,867 shs
SIGA Siga Technologies	$3.11 +5.4%	$3.19	$2.83 ▼ $8.46	$211.96M	1.1	492,298 shs	720,715 shs
TBPH Theravance Biopharma	$17.03	$17.04	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+2.75%	-2.05%	-8.27%	-19.19%	+86.72%
COLL Collegium Pharmaceutical	+0.21%	+3.17%	+7.77%	-33.59%	-34.27%
SIGA Siga Technologies	+5.42%	-2.81%	-7.99%	-1.27%	-62.07%
TBPH Theravance Biopharma	0.00%	0.00%	0.00%	+0.77%	+11.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.88	66.67% Upside
COLL Collegium Pharmaceutical	2.78	Moderate Buy	$48.71	105.29% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A
TBPH Theravance Biopharma	2.00	Hold	$19.00	11.57% Upside

Current Analyst Ratings Breakdown

Latest SIGA, ANRO, TBPH, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	ANRO Alto Neuroscience	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/19/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $60.00
10/15/2026	COLL Collegium Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Strong-Buy
10/6/2026	COLL Collegium Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/24/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Dropped Coverage	Neutral
9/23/2026	COLL Collegium Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$50.00
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$45.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$45.00
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
COLL Collegium Pharmaceutical	$780.57M	0.99	$15.21 per share	1.56	$9.54 per share	2.49
SIGA Siga Technologies	$94.57M	2.36	$0.35 per share	8.86	$2.78 per share	1.12
TBPH Theravance Biopharma	$104.31M	8.48	N/A	N/A	$5.86 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
COLL Collegium Pharmaceutical	$62.87M	$1.24	3.39	4.03	0.74	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/9/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$1.01	16.86	21.02	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest SIGA, ANRO, TBPH, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ANRO Alto Neuroscience	-$0.6735	N/A	N/A	N/A	N/A	N/A
11/10/2026	Q3 2026	TBPH Theravance Biopharma	$0.24	N/A	N/A	N/A	$21.95 million	N/A
11/5/2026	Q3 2026	COLL Collegium Pharmaceutical	$1.86	N/A	N/A	N/A	$216.03 million	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
COLL Collegium Pharmaceutical	3.32	1.03	0.84
SIGA Siga Technologies	N/A	21.72	16.48
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
COLL Collegium Pharmaceutical	N/A
SIGA Siga Technologies	55.40%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
COLL Collegium Pharmaceutical	1.85%
SIGA Siga Technologies	2.73%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	Optionable
COLL Collegium Pharmaceutical	423	32.56 million	31.95 million	Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable

SIGA, ANRO, TBPH, and COLL Headlines

Recent News About These Companies

Theravance Biopharma (TBPH) Projected to Announce Quarterly Earnings on Tuesday

November 3 at 12:25 PM | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Average Price Target of $19.40

October 17, 2026 | marketbeat.com

Zymeworks completes $17 per share Theravance deal

September 28, 2026 | grafa.comG

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell Small Cap Completeness Index

September 24, 2026 | marketscreener.comM

Theravance Biopharma, Inc. annonce des changements au sein de son conseil d’administration, effectifs au 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Theravance Biopharma, Inc. annonce la démission de Rick E Winningham de son poste de directeur général, effective le 23 septembre 2026

September 24, 2026 | zonebourse.comZ

Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.

September 24, 2026 | de.marketscreener.comD

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI Index

September 23, 2026 | marketscreener.comM

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI Index

September 22, 2026 | marketscreener.comM

Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow

September 18, 2026 | seekingalpha.com

Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 18, 2026 | insidertrades.com

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

September 9, 2026 | zacks.com

Theravance Biopharma Inc

August 20, 2026 | money.usnews.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

August 15, 2026 | businesswire.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11, 2026 | zacks.com

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | prnewswire.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | financialpost.comF

Theravance Biopharma Stock Dividends | NASDAQ:TBPH | Benzinga

July 13, 2026 | benzinga.com

Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in Stock

July 2, 2026 | insidertrades.com

Theravance Stock Down 3% After Zymeworks Announces Buyout

June 30, 2026 | zacks.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)

June 29, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, ANRO, TBPH, and COLL Company Descriptions

Alto Neuroscience NYSE:ANRO

$22.72 +0.53 (+2.41%)

Closing price 11/3/2026 03:59 PM Eastern

Extended Trading

$22.70 -0.02 (-0.11%)

As of 04:54 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Collegium Pharmaceutical NASDAQ:COLL

$23.73 +0.05 (+0.21%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$24.30 +0.57 (+2.39%)

As of 07:23 AM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Siga Technologies NASDAQ:SIGA

$3.11 +0.16 (+5.42%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$3.10 0.00 (-0.16%)

As of 07:04 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)

As of 11/2/2026

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SIGA, ANRO, TBPH, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SIGA, ANRO, TBPH, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SIGA, ANRO, TBPH, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, ANRO, TBPH, and COLL Company Descriptions

Alto Neuroscience NYSE:ANRO

Collegium Pharmaceutical NASDAQ:COLL

Siga Technologies NASDAQ:SIGA

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SIGA, ANRO, TBPH, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SIGA, ANRO, TBPH, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SIGA, ANRO, TBPH, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, ANRO, TBPH, and COLL Company Descriptions

Alto Neuroscience NYSE:ANRO

Collegium Pharmaceutical NASDAQ:COLL

Siga Technologies NASDAQ:SIGA

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools